In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apellis Pharmaceuticals, Inc.

Latest From Apellis Pharmaceuticals, Inc.

Apellis To Try Again After EMA Rejects Geographic Atrophy Drug

The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.

Commercial Companies

First Nasal Adrenaline Spray Among 10 Products Heading For EU-Wide Approval

The June meeting of the European Medicines Agency's human medicines committee brought mixed fortunes for companies. 10 new products were recommended for pan-EU approval, two drugs were rejected, while the conditional approval of one drug is set to be revoked. PTC Therapeutics again faced disappointment regarding its Duchenne muscular dystrophy drug Translarna, but has vowed to fight back.

Europe Drug Review

US Rejected Drug Odronextamab Among 11 EU Marketing Hopefuls

Regeneron, whose blood cancer treatment odronextamab was recently turned down by the US regulator but not for reasons relating to efficacy or safety, could soon learn whether its product will be among the drugs to get the thumbs up from the CHMP, the European Medicines Agency’s human medicines committee.

Europe Drug Review

Astellas’s US Commercial Head Petroutsas On New Launches

The Japanese pharma’s new US commercial head Michael Petroutsas talked to Scrip about the launches of Veozah and Izervay.

Launches Leadership
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals